Background
To reduce mortality, women with a family history of breast cancer are often screened with mammography before age 50 years. Additional magnetic resonance imaging (MRI) improves sensitivity and is cost-effective for BRCA1/2 mutation carriers. However, for women with a family history without a proven mutation, cost-effectiveness is unclear.
Methods
We evaluated data of the largest prospective MRI screening study (MRISC) . Between 1999 and 2007, 1597 women (8370 woman-years at risk) aged 25 to 70 years with an estimated cumulative lifetime risk of 15% to 50% for breast cancer were screened with clinical breast examination every 6 months and with annual mammography and MRI. We calculated the cost per detected and treated breast cancer. After incorporating MRISC data into a microsimulation screening analysis model (MISCAN), different schemes were evaluated, and cost per life-year gained (LYG) was estimated in comparison with the Dutch nationwide breast cancer screening program (biennial mammography from age 50 to 75 years). All statistical tests were two-sided.
Results
Forty-seven breast cancers (9 ductal carcinoma in situ) were detected. Screening with additional MRI costs $123 672 (€93 639) per detected breast cancer. In increasing age-cohorts, costs per detected and treated breast cancer decreased, but, unexpectedly, the percentage of MRI-only detected cancers increased. Screening under the MRISC-scheme from age 35 to 50 years was estimated to reduce breast cancer mortality by 25% at $134 932 (€102 164) per LYG (3.5% discounting) compared with 17% mortality reduction at $54 665 (€41 390) per LYG with mammography only.
Conclusions
Screening with MRI may improve survival for women with familial risk for breast cancer but is expensive, especially in the youngest age categories. J Natl Cancer Inst;2013;105: [1314] [1315] [1316] [1317] [1318] [1319] [1320] [1321] Breast cancer is the leading cause of cancer death in women worldwide, accounting for 14% of cancer deaths in 2008, mainly from metastatic disease rather than the primary tumor (1) . The risk of metastases in sporadic and familial breast cancer is related to both the size of the breast cancer at detection and the number of axillary lymph nodes involved (2) . It is therefore crucial to diagnose breast cancer in an early stage of disease. With that aim, population breast cancer screening programs for women aged 50 to 69 years have been incorporated in several countries, and they have reduced the death rate from breast cancer (3, 4) .
Approximately 15% to 20% of all female breast cancers occur in women with a family history of breast cancer, in whom no causative hereditary gene mutation has been found (5) . These women have a greater risk of developing breast cancer and at a younger age than the general population (6) . Therefore, to reduce mortality, these women are often offered annual screening with mammography before they are 50 years old (7, 8) .
However, mammography may not be the ideal screening method for all young women. Breast density is high in about 50% of women aged between 40 and 49 years, whereas only 20% to 44% of women in their 60s have dense breast tissue (9, 10) . Increased breast density lowers sensitivity of mammography; moreover, it increases the risk of breast cancer, independent of other factors (11, 12) .
Adding annual magnetic resonance imaging (MRI) to mammo graphy screening strongly increases sensitivity of detection (13) (14) (15) . Yearly screening with MRI is costeffective for women aged 30 to 60 years with a BRCA1 or BRCA2 gene mutation or women who have a 50% chance of being a carrier (16) (17) (18) . For these women, MRI screening is advised by the American Cancer Society, the American College of Radiologists, the United Kingdom's National Institute for Health and Care Excellence (NICE) guideline, and the European guideline of the European Society of breast imaging (19) (20) (21) (22) . For women with a family history without a proven genetic predisposition, guidelines are equivocal (19, 22, 23) .
To the best of our knowledge, no study has been published assessing costeffectiveness of MRI specifically for these women. We evaluate costeffectiveness of additional MRI for women with a familial risk in the largest prospective study, the MRI Screening Study (MRISC) (15) , to date.
Methods

Patient Characteristics
The MRISC was a Dutch multicenter trial comparing efficacy of mammography with MRI for surveillance of women with a heredi tary predisposition for breast cancer from November 1, 1999, to August 1, 2007 (15) . Methods and results have been described pre viously (15) . The study included women aged 25 to 70 years with a familial or genetic predisposition for breast cancer, whose cumula tive lifetime risk (CLTR) according to the modified tables of Claus et al. (24, 25) was 15% or greater, and who gave written informed consent. Women with evident symptoms or a medical history of breast cancer were excluded (15) .
Participants were subdivided into the following risk catego ries on the basis of their estimated CLTR: carriers of the BRCA1, BRCA2, P53, or PTEN mutation or a 50% likelihood of such a muta tion (CLTR ≥50%); a highrisk group (estimated CLTR of 30% to 50%); and a moderaterisk group (estimated CLTR of 15% to 30%). All patients underwent clinical breast examination (CBE) every 6 months and annual mammography and MRI. True cancer status was ascertained by pathology. Of the 1597 participants in the moderate and highrisk groups, the following data were used: number of diagnosed breast cancers, number of interval breast can cer cases, age distribution of the study population, age at cancer diagnosis, tumor characteristics, and attendance rates at successive rounds of the MRISC study. Median followup was 6.4 years.
Statistical Analysis
Breast cancer incidence rates were calculated as the total number of breast cancers detected (including ductal carcinoma in situ) per 1000 womanyears at risk. Differences between the highrisk group and the moderaterisk group in incidence rates, stage distribution, lymph node status, and tumor characteristics were calculated using χ 2 tests or Fisher exact tests, as appropriate. Differences in median age were calculated with the Mann-Whitney U test. A twosided P value less than or equal to .05 was considered statistically significant. Statistical analyses were performed using Statistical Package for the Social Sciences (SPSS), version 17.0.2 (Chicago, IL). All statistical tests were twosided.
Actual Cost Calculation
We calculated the cost per detected breast cancer by dividing the total costs of the MRISC screening program by the number of cancers detected. We also calculated the cost per detected and treated breast cancer by dividing the total costs of screening, diag nosis, and treatment of all carcinomas found in the program by the number of cancers detected. Additionally, screening, diagnosis, and treatment costs per detected breast cancer by age category were calculated.
Microsimulation Screening Analysis (MISCAN)
MISCAN was used to simulate the MRISC trial and evaluate the costeffectiveness of different screening strategies for women with a family history of breast cancer.
MISCAN is a wellvalidated microsimulation model, originally developed to estimate the costeffectiveness of the population based screening program in the Netherlands (3, 4, 26) . In MISCAN, the natural history of breast cancer is modeled as a progression through five preclinical and invasive disease stages (Supplementary Figure 1 , available online). At each preclinical stage, a tumor may either be clinically diagnosed or grow into the next preclinical stage. Screening may detect the tumor in a preclinical stage. Survival after clinical diagnosis or screen detection is based on data of the Dutch nationwide screening program (3, 27) . The improvement of prog nosis after detection by screening is based on the longterm effects of Swedish trials (28) (29) (30) . A detailed description of the model has been published (31) .
Calibration and Application of MISCAN
We developed the MISCAN family history risk model by using the number of women with a family history in the MRISC, age distri bution at entry of the study, duration of followup and screening protocol, attendance, and sensitivity of different screening methods as inputs. Average screening attendance in the MRISC (90%) was used in the model. Test sensitivities, dependent on age, stage, and screening method, were also estimated from the study (15) . Stage specific sensitivities of clinical breast examination (CBE) in women aged 55 years or older were based on the Canadian National Breast Screening study (26) . For women aged less than 50 years old, CBE sensitivity was assumed to be 50% of the sensitivity for women aged greater than 55 years. For women aged 50 to 55 years, all test sensitivities were linearly interpolated. Estimated values for sensi tivities are shown in Supplementary Table 1 (available online).
The model was calibrated using the MRISC number of screens, number of screendetected cancers and interval cancers, cancer stage distribution, and age at diagnosis. Likelihood ratio tests were used to compare the goodness of fit. Parameters for the lifetime incidence, onset of disease, duration of the stages, and stage tran sition probabilities were estimated by minimizing the difference between observed and predicted counts, measured as a sum of the χ 2 quantities using the simplex method of Nelder and Mead (32) . Model parameters are shown in Supplementary Table 2 (available  online) . Using the calibrated model, predictions of number of screens, number of screendetected and interval cancers, stage distribu tion, mortality reduction, and life years gained (LYG) were made for the following screening protocols: 1) yearly mammography combined with CBE ( Figure 1B) ; 2) CBE every 6 months and yearly mammography and MRI combined (MRISC) ( Figure 1E ); 3) yearly MRI, 6 months later mammography combined with CBE ( Figure 1D ); 4) yearly CBE combined with alternating mammog raphy or MRI ( Figure 1C ).
All screening protocols were run in the model starting screening at age 35 years. Separate runs were done ending screening at 50 years and 60 years. Additional runs were done for the most costeffective MRI screening schedule starting screening at 40 years and ending screening at 50 years. All runs included screening by biennial mammography in the national breast cancer screening program until age 75 years, after the end of the screening protocol (23) .
A cohort of 5 million women born in 1975 was simulated. All costs and effects were predicted for a lifetime followup. Results are presented per 1000 women aged 35 years in 2010. Costeffectiveness ratios are expressed as cost per LYG. Mortality reduction, LYG, and costs per LYG are estimated in comparison with the Dutch national screening program, which consists of biennial mammography from the age 50 to 75 years ( Figure 1A ) (23) . Incremental costeffectiveness ratios that compared two alternative screening programs were calculated by dividing the difference in total net costs and the difference in LYG between two alternative screening policies. Policies that were estimated to be both more expensive and less effective were referred to as dominated, and no incremental costeffectiveness ratios were calculated. Incremental costeffectiveness ratios were expressed as additional cost per additional LYG. In order to weigh costs and health gains in relation to the time at which they occur, costs and effects were discounted at an annual rate of 3.5% (33) .
A CLTR of 16% was used as an agespecific incidence function; sensitivity analyses of the most MRI costeffective strategy were performed increasing CLTR to 26%. Further sensitivity analyses were performed by varying key model parameters (ie, test sensitiv ity and costs of MRI and mammography).
Costs
Costs of screening and additional investigations of each partici pant were taken into account using the information in the MRISC. Additional investigations were defined as all diagnostic tests con ducted because of an "uncertain" or "suspicious" screening test and included ultrasonography with or without fineneedle aspi ration, histologic biopsy, and repeating mammography or MRI (15) . Costs were calculated in Euros (€) (converted to US dollars [$] for publication). The number of investigations performed in the study was used for calculation of the screening and diagnostic costs (Supplementary Table 3, available online) . Costs of systemic treatment were based on current national guidelines (23). Her2 status was not routinely determined during the whole period of the MRISC study. For calibration of MISCAN, we assumed that 30% of patients receiving systemic therapy would be Her2positive and, according to current guidelines, should receive Trastuzumab (34, 35) 
results
Tumor Characteristics
Fortyseven breast cancer cases, of which nine were ductal carci noma in situ (19%), were diagnosed in 8370 woman years screened. Two (4%) of the breast cancers were interval carcinomas. Table 1 * All percentages are calculated vertically. Two-sided P value for difference between two risk groups, differences in stage distribution, lymph node status, and tumor characteristics were obtained from χ 2 or Fisher exact tests, as appropriate. Differences in median age were calculated from the Mann-Whitney U test. All statistical tests were two-sided. CI = confidence interval; DCIS = ductal carcinoma in situ; ER = estrogen receptor; Her2 = human epidermal growth factor 2; N = nodal status; PR = progesterone receptor. † Missing size of one tumor. ‡ Except DCIS. § Missing data of two patients.
group (estimated CLTR of 15% to 30%) was not lower than in the highrisk group (estimated CLTR of 30% to 50%). There also was not a statistically significant difference between the tumor stage and characteristics in the highrisk group compared with the moderate risk group; therefore costeffectiveness calculations were assumed similar in both groups, and a subdivision was no longer made.
Actual Costs
The cost per detected cancer by screening with CBE, mammo graphy, and MRI was $123 672 (€93 639). Table 2 describes costs per detected cancer by age category, separately for screening, diagnosis, treatment, and overall costs. Because there were no tumors detected in the group of women aged less than 30 years, total overall costs instead of costs per detected cancer are depicted. After adding treatment costs, the cost per detected and treated cancer was $133 760 (€101 277). The costs per detected and treated cancer decreased in increasing age categories, most likely because of the higher cancer incidence rate in the older age categories (Figure 2) . However, the percentage of MRIonly detected cancers increased in older age cohorts.
Cost-Effectiveness of Different Screening Strategies
After calibration, the model predicted distribution of cancers detected per age category (Supplementary Figure 2 , available online) and stage distribution quite well (Supplementary Figure 3 , available online). Using the model, we estimated the effects and costs of screening women with a CLTR for breast cancer between 15% and 50%, with biennial mammography screening from ages 50 to 75 years, the protocol of the current Dutch nationwide breast cancer screening program, compared with no screening. This would lead to an estimated mortality reduction of 37% at a cost per LYG of $14 922 (€11 298) (costs per LYG are 3.5% discounted).
An additional mortality reduction of 17% at a cost per LYG of $54 665 (€41 390) can be gained if women are also screened with annual mammography and CBE from age 35 to 50 years, according to guidelines for women with high familial risk.
Screening under the MRISC scheme (CBE every 6 months and annual mammography and MRI from age 35 to 50 years followed by biennial mammography until 75 years) would lead to a mortal ity reduction of 25%, at a cost per LYG of $134 932 (€102 164) compared with screening with biennial mammography from age 50 to 75 years. Screening annually with MRI followed by mammography and CBE 6 months later is more efficient than screening under the MRISC protocol because it also leads to an estimated mortality reduction of 25% but decreases costs to $118 936 (€90 053) per LYG.
The most costeffective MRI screening scheme consisted of alternating screening with mammography in year 1 and MRI in year 2. This gave an estimated mortality reduction of 21% at a cost per LYG of $79 654 (€60 310). When performing sensitivity analyses of this screening scheme, costs per LYG varied between $47 854 (€36 233) and $90 139 (€68 249) (Supplementary Table 5 , available online). If the start of this scheme was postponed until 40 years of age, mortality reduction decreased to 18% at a cost per LYV of $60 267 (€45 631). Further results, depicted per 1000 women screened, are presented in Tables 3 and 4 .
Discussion
We evaluated costeffectiveness of adding yearly MRI to the screen ing schedule for women with a familial risk in the MRISC prospective study. The costs of diagnosis and treatment per detected cancer in our study were $133 760 (€101 277) over all age categories. Costs strongly and continuously decreased with increasing age, most likely because of the higher incidence rate in the older age categories. Although * All costs are in 2013 US dollars with Euros in parentheses. MRI = magnetic resonance imaging. † Percentage of carcinomas or ductal carcinomas in situ detected by MRI, but not by mammography ‡ Because there were no tumors detected in this group, costs mentioned are total costs for the women screened in this group.
Figure 2.
Costs of diagnosis and treatment per detected cancer by age. Costs decreased in increasing age categories, most likely because of the lower cancer incidence rate in the younger age categories. cost per detected and treated breast cancer was most expensive in the youngest age categories, one would expect additional MRI also to be most useful, as breast density is more often high in premenopausal women (9, 10) , which decreases sensitivity of mammography, but not of MRI (11) . Unexpectedly, the percentage of MRIonly detected cancers increased with rising age. MRI sensitivity was also higher in older women in a recent study (36) , but numbers were small, and this needs confirmation in an independent series. We show MRI screening to be expensive, especially in young women. Our results might seem difficult to translate to other practices because costs of mammography and MRI differ greatly between institutions and countries. However, by comparing the ratio of the MRI/mammography costs (approximately 3.5 in our study) a reasonable estimate can be made.
Estimated with MISCAN, the cost per LYG is approximately 2.5 times higher when MRI is added to annual screening with mammography and CBE, but estimated mortality reduction rises from 17% to 25%, caused by a shift in stage at detection of breast cancer. A less costly, quite effective alternative-alternating screen ing with mammography in year 1 and MRI in year 2-needs con firmation in clinical practice. Also, screening closer to the expected age at onset may reduce costs (37) .
We have used the largest database currently available to assess the costeffectiveness of MRI screening in women with a famil ial risk for breast cancer without a proven genetic predisposition. Although studies have been published that analyze costeffective ness of MRI screening for women with hereditary risk, our study is the first to assess this specifically for nonBRCA1/2 women (16) (17) (18) (38) (39) (40) . Furthermore, no studies taking costs of treatment into account have been published, and none of the published studies assess costs per age category.
Our study differs from others performed in various aspects. Three studies (17, 18, 39) published data solely on BRCA1/2 mutation car riers. The costeffectiveness article of the MARIBS study included, but did not analyze separately, women without a proven BRCA1/2 mutation (16). Their nonBRCA1/2 group was small, with 12 inva sive carcinomas detected in 419 women (14) . Furthermore, no treat mentrelated costs were taken into account, and no cost per LYG was estimated. In two recent studies, costeffectiveness analyses were done on estimates based on published data of several prospective MRI screening cohort studies. However, because limited data were published on tumor sizes and probability of nodal involvement for interval tumors, essential data were missing in their analyses (38, 40) .
Our study has some limitations. The estimated CLTR is based on modified tables of Claus (24) , which only take familial risk into account. Other models incorporate additional risk factors. However, risk estimates for the same woman vary greatly with different models (41) . Current risk models have wide confidence intervals, when estimating risk at the personal level and even in large groups as shown in the MRISC study. Therefore, the divi sion into a moderate and highrisk group in the MRISC does not seem justified (41, 42) . This most likely explains our compa rable incidence rate in the two risk groups. Second, survival data of patients with screendetected tumors that are treated with new targeted therapies like Trastuzumab are not yet available (28) (29) (30) . Furthermore, both increasing experience with MRI screening (43) and recent advances in MRI technology and methods may improve results. Still, because costeffectiveness is largely determined by cancer incidence and basic screening costs, these effects are limited.
For future research, women with a familial risk who have high breast density might be an interesting group. The results of a ran domized, controlled trial currently in progress may clarify cost effectiveness for this group (44) .
In conclusion, screening with additional MRI is expensive, but it can improve survival for women with familial risk for breast cancer. Still, it may be more costeffective in select groups.
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